Business
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial enrollment following DSMB recommendation to proceed to second dose level CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and dev
About this update from Promis Neurosciences Inc.
[{"type":"image","alt":"ProMIS Neurosciences Inc.","displaySize":"","headline":null,"caption":"ProMIS Neurosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UIdpZ5Ja0S7N6QhO5P0RBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b","width":300,"height":125}},"lazy":false},{"type":"text","content":"Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310","length":116,"tagName":"p"},{"type":"text","content":"Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD","length":114,"tagName":"p"},{"type":"text","content":"Progress with trial enrollment following DSMB recommendation to proceed to second dose level","length":92,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced it has been invited to present an overview of its ongoing PRECISE-AD trial in Alzheimer’s Disease (AD) and its proprietary Discovery Platform, EpiSelectTM, at the Alzheimer’s Association International Conference 2025 (AAIC) taking place in Toronto, Canada from July 27-31, 2025.","length":717,"tagName":"p"},{"type":"text","content":"“We are pleased to share further details of our ongoing Phase 1b PRECISE-AD clinical trial evaluating PMN310, our novel therapeutic candidate for Alzheimer’s disease,” said Dr. Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences. “PRECISE-AD was intentionally designed with a robust framework to assess both the safety and potential signs of efficacy of PMN310. PMN310 is designed to selectively target toxic amyloid-beta oligomers, which are considered a primary driver of Alzheimer’s disease, while aiming to reduce the risk of safety issues...